Latest Pharmaceutical Distribution News

EBOS Group Limited has updated its interim dividend details for the six months ending December 2025, confirming a fully franked ordinary dividend and a supplementary dividend, alongside a Dividend Reinvestment Plan offering a 2% discount.

EBOS Group Limited has updated its interim dividend announcement, specifying the Dividend Reinvestment Plan strike price and confirming payment details for the six-month period ending December 2025.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.

EBOS Group Limited reported a solid 13% increase in revenue for the first half of FY2026, alongside a 13% rise in net profit attributable to owners, while maintaining its interim dividend.

ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.

EBOS Group Limited has updated its Dividend Reinvestment Plan rules, offering shareholders new ways to reinvest dividends into additional shares. The changes, effective immediately, provide greater flexibility and maintain board discretion over share issuance terms.

Sigma Healthcare’s 2025 AGM reveals a robust year of transformation post-merger with Chemist Warehouse, highlighted by upgraded synergy targets and impressive financial gains.

EBOS Group Limited has updated its final dividend details for the six months ending June 2025, confirming a fully franked ordinary dividend and specifying the Dividend Reinvestment Plan strike price.

Sigma Healthcare reports a robust FY25 performance post-merger with Chemist Warehouse Group, delivering strong revenue growth and upgraded synergy targets. The company signals continued expansion and efficiency gains heading into FY26.

EBOS Group Limited reported a 7% drop in revenue and a 21% fall in net profit for FY2025, reflecting ongoing cost pressures and restructuring impacts. The company declared a final dividend, signaling cautious optimism despite the earnings setback.